AbbVie Inc. (ABBV)
ABBV vs. MRK: An Oncology-Immunology Showdown for Investors
ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to power earnings into 2029 bode well.
AbbVie Call Options Spike 2,599%: Tracking the Big Bet
Unusual market activity is often the first sign that big changes are coming to a stock. Professional traders and large institutions frequently use the options market to place high-conviction bets before major news becomes public.
AbbVie (ABBV) Stock Dips While Market Gains: Key Facts
AbbVie (ABBV) reached $216.75 at the closing of the latest trading day, reflecting a -2.32% change compared to its last close.
AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AbbVie plans to build out its presence in obesity market
AbbVie said on Wednesday it is seeking to expand its presence in the fast-growing market for obesity treatments, leaning on the weight-loss drug it licensed last year from Danish biotech Gubra.
Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon
AbbVie strikes a Trump drug-pricing pact and a $5.6B cancer licensing deal, cutting U.S. prices while expanding its oncology pipeline.
Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Will AbbVie's Oncology Segment Support Top-line Growth in Q4 Earnings?
ABBV's oncology unit is expected to post nearly 4% Q4 sales growth, as newer drugs offset weakness from declining Imbruvica demand.
AbbVie Strikes $100 Billion Investment Deal With Trump, Will Lower Medicaid Prices
As part of the three-year deal, the Trump administration exempted AbbVie from tariffs and future pricing mandates, the company said.
Abbvie, US reach agreement to cut drug prices
Abbvie reached a three-year agreement with U.S. President Donald Trump's administration to provide low prices in Medicaid through TrumpRx, and pledged $100 billion over the next decade for research and development in the U.S., the company said on Monday.
